source
- Amgen reports positive Phase 3 results for Sjögren's drug; Novartis announces $900M radioligand partnershipAmgen said its CD40 ligand antagonist dazodalibep met the primary endpoint in a Phase 3 trial for Sjögren's syndrome, marking a notable achievement for the company. Novartis disclosed a $900 milli…
- HHS rolls out new FDA rule to allow non-animal testing methods in drug developmentThe Department of Health and Human Services announced a new set of strategies aimed at shifting drug development away from animal testing toward human-based research methods. The FDA issued a fina…